Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
Assay Drug Dev Technol ; 6(2): 213-23, 2008 Apr.
Article in English | MEDLINE | ID: mdl-18471075

ABSTRACT

The life-threatening consequences of acquired, or drug-induced, long QT syndrome due to block of the human ether-a-go-go-related gene (hERG) channel are well appreciated and have been the cause of several drugs being removed from the market in recent years because of patient death. In the last decade, the propensity for block of the hERG channel by a diverse and expanding set of compounds has led to the requirement that all new drugs be tested for hERG channel block in a functional patch-clamp assay. Because of the need to identify potential hERG blockers early in the discovery process, radiometric hERG binding assays are preferred over patch-clamp assays for compound triage, because of relative advantages in speed and cost. Even so, these radiometric binding assays are laborious and require dedicated instrumentation and infrastructure to cope with the regulatory and safety issues associated with the use of radiation. To overcome these limitations, we developed a homogeneous, fluorescence polarization-based assay to identify and characterize the affinity of small molecules for the hERG channel and have demonstrated tight correlation with data obtained from either radioligand binding or patch-clamp assays. Key to the development of this assay was a cell line that expressed highly elevated levels of hERG protein, which was generated by coupling expression of the hERG channel to that of a selectable cell surface marker. A high-expressing clone was isolated by flow cytometry and used to generate membrane preparations that contained >50-fold the typical density of hERG channels measured by [(3)H]astemizole binding. This strategy enabled the Predictor (Invitrogen, Carlsbad, CA) hERG fluorescence polarization assay and should be useful in the development of other fluorescence polarization-based assays that use membrane proteins.


Subject(s)
Ether-A-Go-Go Potassium Channels/metabolism , Fluorescence Polarization/methods , CD8 Antigens/physiology , Cell Line , Cell Membrane/drug effects , Cell Membrane/metabolism , Data Interpretation, Statistical , Drug Evaluation, Preclinical/methods , Electrophysiology , Ether-A-Go-Go Potassium Channels/drug effects , Flow Cytometry , Fluorescent Dyes , Genetic Engineering , Humans , Immunohistochemistry , Membrane Potentials/physiology , Membrane Proteins/physiology , Patch-Clamp Techniques , Radioligand Assay
2.
Biochemistry ; 46(3): 683-95, 2007 Jan 23.
Article in English | MEDLINE | ID: mdl-17223690

ABSTRACT

The interactions of the ligand binding domain (LBD) of androgen receptor (AR) and the AR T877A mutant, found in prostate cancer, with peptides from coactivator and corepressor proteins or random phage display peptides were investigated using in vitro time-resolved fluorescence resonance energy transfer (TR-FRET). Interaction of wild-type AR LBD with the random phage display peptide D11FxxLF was observed with dihydrotestosterone (DHT), testosterone, R1881, estradiol, spironolactone, progesterone, and cortisol resulting in distinct dose dependency (EC50) values for each ligand and correlating well with the reported rank order potency of these agonists. Increasing concentrations of cyproterone acetate and mifepristone resulted in more complete disruption of the DHT-mediated AR-D11FxxLF peptide interaction, while flutamide, hydroxyflutamide, and bicalutamide caused only partial disruption of the complex. The mutant AR T877A LBD exhibited increased binding affinities for all ligands tested except for bicalutamide, mifepristone, DHT, and R1881 in a competitive binding assay as compared to wild-type AR LBD. This mutation was also characterized by increased ligand potency for agonist-induced peptide recruitment. Although usually an antagonist, hydroxyflutamide was more potent in the recruitment of D11FxxLF or an SRC3-1 LXXLL motif to AR T877A LBD than AR LBD. The antagonist cyproterone acetate behaved as a full antagonist of D11FxxLF recruitment to AR LBD and AR T877A LBD but as a more potent agonist in the recruitment of SRC3-1 to AR T877A LBD. These results suggest that the AR T877A mutation affects both ligand affinity and ligand dose dependency for peptide recruitment and may explain in part the altered responses of antagonists and increased transcriptional activation reported in androgen-independent prostate cancers.


Subject(s)
Oligopeptides/chemistry , Receptors, Androgen/genetics , Receptors, Androgen/metabolism , Amino Acid Sequence , Amino Acid Substitution , Androgen Antagonists/pharmacology , Anilides/pharmacology , Animals , Cyproterone Acetate/pharmacology , Dihydrotestosterone/metabolism , Fluoresceins/chemistry , Fluorescence Resonance Energy Transfer , Flutamide/analogs & derivatives , Flutamide/pharmacology , Ligands , Mifepristone/pharmacology , Nitriles , Rats , Tosyl Compounds
3.
Bioorg Med Chem ; 14(19): 6737-44, 2006 Oct 01.
Article in English | MEDLINE | ID: mdl-16859909

ABSTRACT

Based on the catalysis mechanism of urease, a homologous series of 10 cysteine derivatives (CysDs) was designed and synthesized, and their inhibitory activities were evaluated for microbial ureases (Bacillus pasteurii, BPU, and Proteus mirabilis, PMU) and for a plant urease [jack bean (Cavavalia ensiformis), JBU]. As already described, thiol-compounds might inhibit urease activity by chelating the nickel atoms involved in the catalysis process. In contrast to cysteine, which has been reported to be a very weak urease inhibitor, we verified a potential inhibitory activity of these CysDs. The kinetic data demonstrate that thiol derivatives are more effective than the respective thioether derivatives. Besides, thiol-CysDs had a reduced activity in acidic pH (5.0). Lineweaver-Burk plots indicated that the nature of inhibition was of noncompetitive type for all 10 compounds, with the minimum Ki value of 2 microM for N,N-dimethyl L-cysteine. It is proposed that these classes of compounds are more potent inhibitors of the bacterial ureases, compared with the plant-originated urease. Since microbial urease is directly involved in the infection process of many pathological organisms, this work demonstrates that thiol-CysDs represent a class of new potential urease inhibitors.


Subject(s)
Bacteria/enzymology , Cysteine/analogs & derivatives , Cysteine/pharmacology , Enzyme Inhibitors/chemical synthesis , Enzyme Inhibitors/pharmacology , Fabaceae/enzymology , Urease/antagonists & inhibitors , Bacteria/drug effects , Bacterial Proteins/genetics , Bacterial Proteins/metabolism , Cysteine/chemical synthesis , DNA Damage/drug effects , Fabaceae/drug effects , Structure-Activity Relationship
4.
Assay Drug Dev Technol ; 3(6): 613-22, 2005 Dec.
Article in English | MEDLINE | ID: mdl-16438657

ABSTRACT

Direct measurement of the fluorescence lifetime (FLT) of a fluorescent label is an emerging method for high-throughput screening. Changes in the fluorescence lifetime can be correlated to changes in the non-radiative relaxation pathway(s) for the excited state of the label. These pathways can be environmentally sensitive, such as when a labeled analyte is free in solution versus bound to a receptor. Because lifetime is an intrinsic property of a fluorophore, it is not concentration dependent, and therefore has advantages similar to those of ratiometric fluorescent techniques such as fluorescence resonance energy transfer or fluorescence polarization. We have applied the FLT measurement technique to a screen of a small compound library in order to identify compounds that bind to the progesterone receptor, and compared the results to those obtained by performing the assay in fluorescence polarization mode. Each readout modality showed excellent Z'; values, with the FLT readout performing slightly better in this respect. Interfering compounds could be rapidly identified for either assay format by comparing the results between the two formats.


Subject(s)
Fluorescence Polarization , Fluorescent Dyes , Receptors, Progesterone/metabolism , 17-alpha-Hydroxyprogesterone/metabolism , Binding, Competitive , Drug Evaluation, Preclinical/methods , Fluorescence Polarization/methods , Fluorescent Dyes/chemistry , Hormone Antagonists/metabolism , Humans , Ligands , Mifepristone/metabolism , Progesterone/metabolism , Receptors, Progesterone/chemistry , Reproducibility of Results
SELECTION OF CITATIONS
SEARCH DETAIL
...